Dr. Steven Joel Feigenberg, MD

Dr. Feigenberg practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Feigenberg's NPI, 1790705754, was assigned on July 20, 2006. Dr. Feigenberg graduated from Drexel University College of Medicine/Hahnemann University in 1997. Dr. Feigenberg holds Pennsylvania license MD419311.

Dr. Feigenberg's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. Feigenberg's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. Dr. Feigenberg is also affiliated with Penn Presbyterian Medical Center. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Feigenberg to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feigenberg practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Feigenberg's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Feigenberg is licensed in Pennsylvania.

CMS data shows 1,273 Medicare services from Dr. Feigenberg across 19 procedure codes in 2024, for 440 Medicare patients. Medicare paid $97,394 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 440 Medicare patients who saw Dr. Feigenberg in 2024. The largest group is 65 to 74, with 226 patients. 75% of them have high cholesterol, and 73% have cancer. 10% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feigenberg's median patient age at 64, with 49% women.

In 2024, Dr. Feigenberg wrote 98 Medicare Part D claims for 36 patients. 94% of them were for generic drugs. CMS names the drug for 36 of them, across 3 drugs with 11 or more claims each, at $476 in total drug cost. In 2023, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Feigenberg for performance year 2024, reported individually. Dr. Feigenberg accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Feigenberg as offering telehealth.

Dmand AI links 101 papers to Dr. Feigenberg, published from 2011 to 2025. 2023 was the busiest year, with 15. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Breast Neoplasms. Dr. Feigenberg has published most often in Int J Radiat Oncol Biol Phys. Dr. Feigenberg's most frequent co-authors are Keith Cengel, MD, PhD, Charles Brian Simone, MD and Elizabeth May Nichols, MD.

Dmand AI links Dr. Feigenberg to 10 clinical trials, 2 of them phase 2/3 studies. 6 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Non-Small-Cell Lung. NRG Oncology sponsors the most, 3.

CMS Open Payments shows 5 general payments to Dr. Feigenberg from 3 drug and device companies from 2020 to 2025. Speaker and faculty fees make up the largest share, 59% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,746.

Dr. Feigenberg graduated from Drexel University College of Medicine/Hahnemann University in 1997.